<DOC>
	<DOCNO>NCT02454062</DOCNO>
	<brief_summary>A Phase I , Open-Label , International , Multicenter , Non-Randomized , Dose-Escalating Safety , Tolerance Pharmacokinetic Study Oral Administration TAS-114 Combination S-1 Twice Daily Schedule 14 Days Patients Advanced Solid Tumors .</brief_summary>
	<brief_title>A Trial TAS-114 Combination With S-1</brief_title>
	<detailed_description>This open-label , non-randomized , dose-escalation Phase I study TAS-114 administered combination S-1 , evaluate safety , tolerability , pharmacokinetics preliminary antitumor activity TAS-114/S-1 regimen patient advance solid tumor . The study conduct two part : Dose-Escalation Phase ( Part 1 ) determine MTD ; Expansion Phase ( Part 2 ) evaluate safety preliminary efficacy MTD . Patients receive study medication accord propose treatment schedule disease progression ( PD ) , occurrence intolerable side effect , removal Investigator withdrawal consent . A patient consider discontinue study treatment TAS-114 discontinued . Male female patient age 18 year old confirm advanced solid tumor ( ) standard therapy exist . TAS-114/S-1 administer BID 14 day follow 7-day recovery period , every 21 day ( 1 cycle ) patient advance solid tumor .</detailed_description>
	<criteria>1 . Has provide write informed consent . 2 . Is â‰¥18 year age 3 . Has histologically cytologically confirm advanced metastatic solid tumor ( ) standard therapy exist . 4 . Expansion Phase : Has least one measurable lesion 5 . Is able take medication orally ( e.g. , feed tube ) . 6 . Has adequate organ function 7 . Women childbearing potential must negative pregnancy test ( urine serum ) within 7 day prior start study drug . 8 . Is willing able comply schedule visit study procedure . 1 . Has receive treatment proscribed treatment within specified time frame prior study drug administration . 2 . Has serious illness medical condition ( ) 3 . Is receive concomitant treatment drug may interact S1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Phase I</keyword>
	<keyword>Solid Tumors</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>MTD</keyword>
</DOC>